Kenneth Burns
Pulmonary Disease · Greensboro, NCNPI 1962768580
Payments from drug & device makers
Across 163 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$500
- Boehringer Ingelheim$372
- AstraZeneca$316
- Mallinckrodt Hospital Products Inc.$200
- Grifols USA, LLC$142
- Gilead$139
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,975100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 29 | $500 |
| Boehringer Ingelheim | 17 | $372 |
| AstraZeneca(2 entities) | 21 | $316 |
| Mallinckrodt Hospital Products Inc. | 9 | $200 |
| Grifols USA, LLC | 6 | $142 |
| Gilead | 7 | $139 |
| Mylan Specialty L.p. | 8 | $114 |
| Intuitive Surgical | 1 | $100 |
| United Therapeutics Corporation | 5 | $95 |
| Merck | 6 | $89 |
| Inogen, Inc. | 6 | $76 |
| Collegium Pharmaceutical, Inc. | 4 | $75 |
| Actelion Pharmaceuticals US, Inc. | 4 | $75 |
| Regeneron Healthcare Solutions, Inc. | 3 | $61 |
| Advanced Respiratory, Inc | 3 | $55 |
| Viatris Specialty LLC | 2 | $47 |
| Philips North America LLC | 3 | $44 |
| Hospira, Inc. | 3 | $43 |
| Novartis | 2 | $42 |
| ANI Pharmaceuticals, Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Shionogi Inc | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Insmed, Inc. | 2 | $29 |
| Genentech USA, Inc. | 2 | $27 |
| Pfizer | 2 | $27 |
| Astellas Pharma US Inc | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $20 |
| Amgen | 1 | $20 |
| Bio Products Laboratory USA, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Electromed, Inc. | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$123
How this compares
$2,975 in reported general payments places this provider in the 55th percentile of 393 pulmonary disease providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $31,596 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $12,258 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,499 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,403 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,382 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $977 |
| Ventolin HfaAlbuterol Sulfate | 16 | $845 |
| Montelukast Sodium | 11 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $500 | $38,09556 claims |
| AstraZenecaBreztri Aerosphere | $316 | $12,25817 claims |
| Boehringer IngelheimStiolto Respimat | $372 | $5,40311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Greensboro
- Murali RamaswamyGreensboro$2M
- Michael WertGreensboro$412K
- Selwyn SpangenthalCharlotte$7M
- Thomas SternHuntersville$5.2M
- Laurie SnyderDurham$3.8M
- Scott PalmerDurham$3.8M
- Michael PritchettPinehurst$2.2M
- Anup BanerjeeGastonia$2.1M
- Hubert FordChapel Hill$2M
- Mikell JarrattGastonia$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.